What does it mean when mass spectrometry identifies TTR and lambda proteins in ocular amyloidosis without specifying the subtype?
When mass spectrometry detects both TTR (transthyretin) and lambda light-chain proteins in eye tissue, it confirms amyloid deposits are present but doesn't tell the full story. This test Show Full Answer
What does it mean when mass spectrometry identifies TTR and lambda proteins in ocular amyloidosis without specifying the subtype?
When mass spectrometry detects both TTR (transthyretin) and lambda light-chain proteins in eye tissue, it confirms amyloid deposits are present but doesn't tell the full story. This test identifies which proteins are forming the amyloid, but it can't determine whether the condition is limited to the eye (localized) or affecting multiple organs (systemic), nor can it distinguish between hereditary and wild-type forms.
This is actually a common situation because mass spectrometry is excellent at identifying protein types but needs to be paired with other tests to understand the bigger picture of your condition. The next diagnostic steps typically include:
Genetic Testing
A blood test to check for mutations in the TTR gene will determine if you have hereditary ATTR amyloidosis or wild-type ATTR. If a mutation is found, it's hereditary; if not, it's wild-type.
Systemic Evaluation
To determine if amyloidosis is localized to your eyes or systemic, your healthcare team will likely order:
- Bone marrow biopsy to check for abnormal plasma cells throughout the body
- Blood and urine tests for light-chain proteins
- Additional biopsies of other organs if needed
- Tests to check organ function (heart, kidneys, nerves)
Imaging and Specialized Tests
An echocardiogram can check heart function, and other imaging may assess whether amyloid deposits exist in other organs beyond the eyes.
Since hereditary ATTR amyloidosis is strongly linked to eye involvement and runs in families, sharing your family history with your doctor is particularly important for guiding these next steps.
January 29
Join
Your Privacy Choices
